Prot #IMSA101-103: Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignan

Project: Research project

Project Details

StatusActive
Effective start/end date12/15/23 → 12/15/26

Funding

  • Clinipace, Inc. (Prot# IMSA101-103 // Prot# IMSA101-103)
  • ImmuneSensor Therapeutics, Inc. (Prot# IMSA101-103 // Prot# IMSA101-103)